The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. (Q50701935)

17 March 2018

title

The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. (English)

1 reference

17 March 2018

0 references

Avi Amrami-Weizman

1

1 reference

17 March 2018

Rachel Maayan

2

1 reference

17 March 2018

Irit Gil-Ad

3

1 reference

17 March 2018

Artashez Pashinian

4

1 reference

17 March 2018

Camil Fuchs

5

1 reference

17 March 2018

Moshe Kotler

6

1 reference

17 March 2018

Michael Poyurovsky

7

1 reference

17 March 2018

publication date

5 July 2013

1 reference

17 March 2018

published in

Psychopharmacology

1 reference

17 March 2018

volume

230

1 reference

17 March 2018

page(s)

23-27

1 reference

17 March 2018

issue

1

1 reference

17 March 2018

https://scigraph.springernature.com/pub.10.1007/s00213-013-3199-1

exact match

0 references

cites work

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Oral dehydroepiandrosterone replacement in older adults: effects on central adiposity, glucose metabolism and blood lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Mortality risk of triglyceride levels in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Dehydroepiandrosterone prevents age-associated alterations, increasing insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Neuroendocrinological mechanisms of actions of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3199-1

Dehydroepiandrosterone-mediated decrease in caloric intake by obese Zucker rats is not due to changes in serum entrostatin-like immunoreactivity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23828160

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23828160

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An open trial of reboxetine in obese patients with binge eating disorder

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23828160

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00213-013-3199-1

1 reference

17 March 2018

PubMed ID

23828160

1 reference

17 March 2018